Dupilumab as a treatment for cutaneous immune-related adverse events induced by immune checkpoint inhibitors: A case series and review of the literature

Immune checkpoint inhibitors have revolutionized cancer treatment. They can induce cutaneous immune-related adverse events. One patient with immune-related eczema and two with immune-related bullous pemphigoid were successfully treated with dupilumab. Guidelines recommend the use of systemic steroid...

Descripción completa

Detalles Bibliográficos
Autores principales: Fournier, Cynthia, Hirsch, Ian, Spreafico, Anna, Butler, Marcus Otho, Dhani, Neesha, Sauder, Maxwell Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
JCMS Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467211/
https://www.ncbi.nlm.nih.gov/pubmed/37654554
http://dx.doi.org/10.1177/2050313X231195462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467211/
https://www.ncbi.nlm.nih.gov/pubmed/37654554
http://dx.doi.org/10.1177/2050313X231195462

Ejemplares similares